相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity
Rami Al Batran et al.
JCI INSIGHT (2019)
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus
Brian W. Gilbert et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Targeting hepatic pyruvate dehydrogenase kinases restores insulin signaling and mitigates ChREBP-mediated lipogenesis in diet-induced obese mice
Cheng-Yang Wu et al.
MOLECULAR METABOLISM (2018)
Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
Rahul Sao et al.
ARCHIVES OF MEDICAL SCIENCE (2018)
Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction
Muhammed Keskin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study
Ju-Sheng Zheng et al.
BMC MEDICINE (2017)
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Joel T. Haas et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
Inhibition of Pyruvate Dehydrogenase Kinase 2 Protects Against Hepatic Steatosis Through Modulation of Tricarboxylic Acid Cycle Anaplerosis and Ketogenesis
Younghoon Go et al.
DIABETES (2016)
Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis
Petra Hirsova et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2015)
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
Stefano Ballestri et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Nonalcoholic Fatty Liver Disease and Severity of Cardiovascular Disease Manifestations
Vasilios G. Athyros et al.
ANGIOLOGY (2013)
Association Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease Complexity in Patients With Acute Coronary Syndrome: A Pilot Study
Mustafa Tarik Agac et al.
ANGIOLOGY (2013)
Comparison between IDMS-traceable Jaffe and enzymatic creatinine assays for estimation of glomerular filtration rate by the CKD-EPI equation in healthy and diabetic subjects
Amanda Veiga Cheuiche et al.
CLINICAL BIOCHEMISTRY (2013)
The global NAFLD epidemic
Rohit Loomba et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Inflammation in Alcoholic Liver Disease
H. Joe Wang et al.
ANNUAL REVIEW OF NUTRITION, VOL 32 (2012)
Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury
John R. Ussher et al.
CARDIOVASCULAR RESEARCH (2012)
Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences
Maria Del Ben et al.
INTERNAL AND EMERGENCY MEDICINE (2012)
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
J. K. Dowman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome
Jeffrey W. Chisholm et al.
DIABETES CARE (2010)
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Vasilios G. Athyros et al.
LANCET (2010)
Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma
Rossana M. Calderon et al.
MAYO CLINIC PROCEEDINGS (2010)
Prescribing Statins to Patients with Nonalcoholic Fatty Liver Disease: Real Cardiovascular Benefits Outweigh Theoretical Hepatotoxic Risk
P. Riley et al.
CARDIOVASCULAR THERAPEUTICS (2009)
Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial
David A. Morrow et al.
CIRCULATION (2009)
Ranolazine improves endothelial function in patients with stable coronary artery disease
Smriti H. Deshmukh et al.
CORONARY ARTERY DISEASE (2009)
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease
Giovanni Targher et al.
ATHEROSCLEROSIS (2007)
Effects of ranolazine on exercise tolerance and HbA(1c) in patients with chronic angina and diabetes
AD Timmis et al.
EUROPEAN HEART JOURNAL (2006)
Evaluation and management of non-alcoholic steatohepatitis
S Ramesh et al.
JOURNAL OF HEPATOLOGY (2005)
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
BR Chaitman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
分享论文
